Business Description
Hemogenyx Pharmaceuticals PLC
ISIN : GB00BQVXM815
Total Employee Number:
16Description
Hemogenyx Pharmaceuticals PLC is clinical-stage biotechnology focused on the discovery, development and commercialisation of treatments relating to the treatment of blood cancers, certain solid cancers, autoimmune diseases, and viral infections. The products under development are designed to address a range of problems that occur with current standard of care treatments. The Group has one reportable segment, the discovery, development, and commercialisation of treatments relating to blood and immune system disorders and viral infections, and administrative functions in the United Kingdom. It has its presence in United Kingdom; and United States.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.79 | |||||
Equity-to-Asset | 0.29 | |||||
Debt-to-Equity | 1.68 | |||||
Debt-to-EBITDA | -0.22 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -12.9 | |||||
3-Year EPS without NRI Growth Rate | 17.4 | |||||
3-Year FCF Growth Rate | 17.1 | |||||
3-Year Book Growth Rate | -47.1 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 19.4 | |||||
9-Day RSI | 30.53 | |||||
14-Day RSI | 38.1 | |||||
3-1 Month Momentum % | 3.98 | |||||
6-1 Month Momentum % | 18.83 | |||||
12-1 Month Momentum % | 369.23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.38 | |||||
Quick Ratio | 1.38 | |||||
Cash Ratio | 1.08 | |||||
Days Payable | 323.4 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -35.1 | |||||
Shareholder Yield % | -9.22 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -1838.04 | |||||
ROA % | -254.85 | |||||
ROIC % | -148.13 | |||||
3-Year ROIIC % | -39.04 | |||||
ROC (Joel Greenblatt) % | -425.61 | |||||
ROCE % | -379.65 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 37.07 | |||||
Price-to-Tangible-Book | 43.42 | |||||
EV-to-EBIT | -5.27 | |||||
EV-to-EBITDA | -5.62 | |||||
EV-to-FCF | -15.57 | |||||
Earnings Yield (Greenblatt) % | -18.96 | |||||
FCF Yield % | -6.91 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Hemogenyx Pharmaceuticals PLC Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -2.565 | ||
| Beta | 0.4196 | ||
| 3-Year Sharpe Ratio | 0.65 | ||
| 3-Year Sortino Ratio | 2.02 | ||
| Volatility % | 277.02 | ||
| 14-Day RSI | 38.1 | ||
| 14-Day ATR (€) | 0.212566 | ||
| 20-Day SMA (€) | 8.7725 | ||
| 12-1 Month Momentum % | 369.23 | ||
| 52-Week Range (€) | 1.47 - 18.9 | ||
| Shares Outstanding (Mil) | 6.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hemogenyx Pharmaceuticals PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Hemogenyx Pharmaceuticals PLC Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-09-30 | In 67 days | ||
| General meeting for 2025 | 2026-06-30 13:00 | 8.55 (-2.29%) | ||
| Annual report for 2025 | 2026-04-30 | 7.70 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-04-30 | 7.70 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-09-30 | 13.30 (+5.56%) | ||
| General meeting for 2024 | 2025-05-29 13:00 | 2.02 (+0.00%) | ||
| Annual report for 2024 | 2025-04-30 | 2.06 (+0.00%) | ||
| Fourth quarter earnings results for 2024 | 2025-04-28 | 2.06 (+0.00%) | ||
| 0.0025:1 Stock Split | 2024-12-13 | 2.80 (+55.56%) | ||
| Second quarter earnings results for 2024 | 2024-09-27 | 6.00 (+11.11%) |
Show
Entries
Hemogenyx Pharmaceuticals PLC Frequently Asked Questions
What is Hemogenyx Pharmaceuticals PLC(FRA:5HU0)'s stock price today?
The current price of FRA:5HU0 is €8.25. The 52 week high of FRA:5HU0 is €18.90 and 52 week low is €1.47.
When is next earnings date of Hemogenyx Pharmaceuticals PLC(FRA:5HU0)?
The next earnings date of Hemogenyx Pharmaceuticals PLC(FRA:5HU0) is 2026-09-30 Est..
Does Hemogenyx Pharmaceuticals PLC(FRA:5HU0) pay dividends? If so, how much?
Hemogenyx Pharmaceuticals PLC(FRA:5HU0) does not pay dividend.
Press Release
Articles on Hemogenyx Pharmaceuticals PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers